D
CRISPR Therapeutics AG CRSP
$56.68 -$1.41-2.43% NASDAQ
Recommendation
Prev Close
$56.68
Volume
1,402,459
Avg Vol (90D)
2,427,506
Market Cap
$5.40B
Dividend & Yield
--
52-Week Range
$30.04 - $78.48
P/E (TTM)
--
EPS (TTM)
-$5.59
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
5/16/2025 - MarketBeat
Nikko Asset Management Americas Inc. Sells 125,618 Shares of CRISPR Therapeutics AG $CRSP
12/14/2025 - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts
12/13/2025 - MarketBeat
2 Healthcare Stocks to Buy Ahead of the New Year
12/12/2025 - Fool.com Headlines
New York State Common Retirement Fund Increases Position in CRISPR Therapeutics AG $CRSP
12/11/2025 - MarketBeat
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?
12/10/2025 - Zacks Investment Research
Is CRISPR Therapeutics (CRSP) Turning Early CTX310 Signals Into a Durable Genetic Medicine Platform?
12/9/2025 - Simply Wall St
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
12/9/2025 - PR Newswire
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
12/9/2025 - CNW Group - News Releases
Guggenheim Capital LLC Sells 37,778 Shares of CRISPR Therapeutics AG $CRSP
12/9/2025 - MarketBeat
Norges Bank Invests $19.77 Million in CRISPR Therapeutics AG $CRSP
12/9/2025 - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
12/8/2025 - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), PROCEPT BioRobotics (PRCT) and Crispr Therapeutics AG (CRSP)
12/8/2025 - TipRanks Financial Blog
CRISPR Therapeutics (CRSP): Reassessing Valuation After Casgevy Approvals and Growing 2025 Revenue Expectations
12/8/2025 - Simply Wall St
Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
12/7/2025 - TipRanks Financial Blog
2 Stocks That Could Soar by 52% and 282%, According to Wall Street
12/7/2025 - Fool.com Headlines
State Board of Administration of Florida Retirement System Acquires New Holdings in CRISPR Therapeutics AG $CRSP
12/7/2025 - MarketBeat
Crispr Therapeutics AG: Stock Surge Amid Challenges
12/6/2025 - TipRanks Financial Blog
CRISPR Therapeutics AG (CRSP, $58.18) price may drop as it broke higher Bollinger Band on Dec 04, 2025
12/5/2025 - Tickeron - Stocks
50,250 Shares in CRISPR Therapeutics AG $CRSP Purchased by Philadelphia Trust Co.
12/5/2025 - MarketBeat
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
12/4/2025 - Seeking Alpha - Long Ideas
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
12/4/2025 - SeekingAlpha
Rhumbline Advisers Buys New Holdings in CRISPR Therapeutics AG $CRSP
12/4/2025 - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Bought by Legal & General Group Plc
12/4/2025 - MarketBeat
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
1/23/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$38.34M
EBITDA (TTM)
-$459.48M
EBIT (TTM)
-$478.14M
Net Income (TTM)
-$488.30M
Balance Sheet
Total Assets (Q)
$2.25B
Total Debt (Q)
$211.02M
Total Liabilities (Q)
$329.33M
Book Value Per Share (Q)
$20.41
Cash Flow
Cash from Operations (TTM)
-$302.49M
Cash from Investing (TTM)
$36.82M
Cash from Financing (TTM)
$326.49M
Net Change in Cash (TTM)
$60.83M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 9 and 13 (est)
Price History
Loading...
Beta
2.05
7-Day Total Return
-2.58%
30-Day Total Return
-11.42%
60-Day Total Return
-9.05%
90-Day Total Return
1.29%
Year to Date Total Return
36.81%
1-Year Total Return
29.47%
2-Year Total Return
-7.73%
3-Year Total Return
11.79%
5-Year Total Return
-62.23%
52-week Low
Apr 07, 2025 - $30.04
52-week High
Oct 08, 2025 - $78.48
Valuation
Market Cap
$5.40B - Mid Cap
Enterprise Value
$3.67B
Price/Sales (TTM)
135.02
Price/Book (Q)
2.78
Dividends and Shares
Shares Outstanding
91.31
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.crisprtx.com
Phone Number
41 41 561 32 77
Address
Baarerstrasse 14
Zug, 6300
Country
Switzerland
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats... more
NASDAQ 12/12/2025 4:00PM Eastern Quotes delayed